AstraZeneca and Tempus AI used contrastive learning to find biomarkers that predict treatment response. Outcome: 15% survival benefit over traditional immuno-oncology trial designs. AI catching what human researchers couldn't. That's not incremental. #AI

→ View original post on X — @svenphilipsen, 2026-03-17 16:00 UTC